RSS
LUXTURNA
Spark Therapeutics reveals payment options for its one-time treatment of a rare retinal disease
US-based company, Spark Therapeutics, has announced a programme of improved access to its one-time gene therapy treatment, LUXTURNA, indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy Read more
